26. Deferred income
The movement in the non-current and current deferred income is detailed in the table below.
(thousands of €) |
Gilead collaboration agreement for filgotinib |
Gilead collaboration agreement for drug discovery platform(1) |
Other deferred income |
Total |
||||
|---|---|---|---|---|---|---|---|---|
On 1 January 2022 |
604,875 |
1,759,828 |
- |
2,364,701 |
||||
Of which current portion |
190,018 |
229,848 |
- |
419,866 |
||||
|
|
|
|
|
||||
Milestones achieved |
18,238 |
|
|
18,238 |
||||
Significant financing component(2) |
7,672 |
|
|
7,672 |
||||
|
|
|
|
|
||||
Revenue recognition of upfront |
(139,655) |
(230,423) |
|
(370,078) |
||||
Revenue recognition of milestones |
(34,777) |
|
|
(34,777) |
||||
|
|
|
|
|
||||
Other movements |
|
|
3,474 |
3,474 |
||||
|
|
|
|
|
||||
On 31 December 2022 |
456,352 |
1,529,405 |
3,474 |
1,989,230 |
||||
Of which current portion |
133,470 |
230,022 |
2,139 |
365,631 |
||||
|
|
|
|
|
||||
Reclassification to liabilities directly associated with assets in disposal group classified as held for sale |
|
|
(60) |
(60) |
||||
Significant financing component(2) |
(645) |
|
|
(645) |
||||
|
|
|
|
|
||||
Revenue recognition of upfront |
(361,412) |
(230,242) |
|
(591,654) |
||||
Revenue recognition of milestones |
(68,027) |
|
|
(68,027) |
||||
|
|
|
|
|
||||
Other movements |
|
|
(1,382) |
(1,382) |
||||
|
|
|
|
|
||||
On 31 December 2023 |
26,268 |
1,299,163 |
2,032 |
1,327,463 |
||||
Of which current portion |
25,054 |
230,070 |
1,146 |
256,270 |
||||
|
||||||||
We refer to note 2 for a detail of the allocation of the transaction price of our collaboration with Gilead and to note 5 and note 7 for a description of our revenue recognition.